137 related articles for article (PubMed ID: 31162548)
1. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
3. FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway.
Wang C; Tan C; Wen Y; Zhang D; Li G; Chang L; Su J; Wang X
Cell Death Dis; 2019 Jun; 10(7):499. PubMed ID: 31235696
[TBL] [Abstract][Full Text] [Related]
4. MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/β-catenin pathway.
Cong J; Gong J; Yang C; Xia Z; Zhang H
BMC Cancer; 2021 Jan; 21(1):2. PubMed ID: 33397320
[TBL] [Abstract][Full Text] [Related]
5. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Cao L; Gao H; Li P; Gui S; Zhang Y
Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
[TBL] [Abstract][Full Text] [Related]
6. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.
Tan Z; Zheng H; Liu X; Zhang W; Zhu J; Wu G; Cao L; Song J; Wu S; Song L; Li J
Oncotarget; 2016 Apr; 7(17):24076-87. PubMed ID: 26992223
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
[TBL] [Abstract][Full Text] [Related]
9. miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2.
Chen HY; Lang YD; Lin HN; Liu YR; Liao CC; Nana AW; Yen Y; Chen RH
Sci Rep; 2019 Jul; 9(1):9687. PubMed ID: 31273221
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-139-5p regulates C2C12 cell myogenesis through blocking Wnt/β-catenin signaling pathway.
Mi L; Li Y; Zhang Q; Zhao C; Peng Y; Yang G; Zheng X
Biochem Cell Biol; 2015 Feb; 93(1):8-15. PubMed ID: 25529604
[TBL] [Abstract][Full Text] [Related]
11. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
12. Curcumin affects autophagy of prolactinoma cells by upregulating miR-206 to exert antitumor effects.
Duan JF; Zhang QJ; Zhu J; Lu JH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23734. PubMed ID: 38764151
[TBL] [Abstract][Full Text] [Related]
13. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
Kong LY; Xue M; Zhang QC; Su CF
Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
[TBL] [Abstract][Full Text] [Related]
15. MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7.
Yue X; Cao D; Lan F; Pan Q; Xia T; Yu H
Neuro Oncol; 2016 Sep; 18(9):1288-96. PubMed ID: 27006177
[TBL] [Abstract][Full Text] [Related]
16. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
17. Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.
Gao Z; Cai L; Lu J; Wang C; Li Q; Chen J; Song X; Chen X; Zhang L; Zheng W; Su Z
Med Sci Monit; 2017 Apr; 23():1827-1833. PubMed ID: 28411401
[TBL] [Abstract][Full Text] [Related]
18. MiR-34a Inhibits Breast Cancer Proliferation and Progression by Targeting Wnt1 in Wnt/β-Catenin Signaling Pathway.
Si W; Li Y; Shao H; Hu R; Wang W; Zhang K; Yang Q
Am J Med Sci; 2016 Aug; 352(2):191-9. PubMed ID: 27524218
[TBL] [Abstract][Full Text] [Related]
19. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
Zhao W; Yang S; Chen J; Zhao J; Dong J
Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
[TBL] [Abstract][Full Text] [Related]
20. TTPAL Promotes Colorectal Tumorigenesis by Stabilizing TRIP6 to Activate Wnt/β-Catenin Signaling.
Gou H; Liang JQ; Zhang L; Chen H; Zhang Y; Li R; Wang X; Ji J; Tong JH; To KF; Sung JJY; Chan FKL; Fang JY; Yu J
Cancer Res; 2019 Jul; 79(13):3332-3346. PubMed ID: 31018940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
